Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | RPS6KA2 | Q15349 | 4/20 | 0.32 |
| ▸ | PRKD2 | Q9BZL6 | 4/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.32 |
| ▸ | LCP2 | Q13094 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22484671 | 1.00 | DPP4 (0.33) | DPP4RPS6KA2PRKD2MAP4K1LCP2 | |
| SCHEMBL22485317 | 0.77 | DPP4 (0.33) | DPP4 | |
| SCHEMBL24535767 | 0.77 | MAP4K1 (0.33) | RPS6KA2PRKD2MAP4K1LCP2 | |
| SCHEMBL21152441 | 0.77 | DPP4 (0.33) | DPP4 | |
| SCHEMBL22485322 | 0.77 | DPP4 (0.33) | DPP4 | |
| SCHEMBL22484753 | 0.70 | — | — | |
| SCHEMBL22484668 | 0.70 | — | — | |
| SCHEMBL22484659 | 0.69 | DPP4 (0.31) | DPP4 | |
| SCHEMBL22484662 | 0.69 | DPP4 (0.31) | DPP4 | |
| SCHEMBL22484660 | 0.69 | DPP4 (0.31) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308193-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308193-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, AIFM1, BCL2 | DPP4 2104/4885RPS6KA2 793/4885PRKD2 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.